- Report
- October 2024
- 180 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 50 Pages
Global
From €2519EUR$2,650USD£2,116GBP
- Report
- May 2024
- 130 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- May 2024
- 138 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- August 2022
- 120 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2023
- 189 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- January 2022
- 120 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- April 2023
- 77 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- July 2024
- 280 Pages
Global
From €2524EUR$2,655USD£2,120GBP
Deferasirox is a hematological drug used to treat iron overload caused by blood transfusions. It is an oral chelator that binds to iron and helps the body to excrete it. Deferasirox is used to reduce iron levels in patients with thalassemia, sickle cell anemia, and other conditions that require frequent blood transfusions. It is also used to treat iron overload in patients with myelodysplastic syndromes and other conditions. Deferasirox is available in tablet form and is taken once daily.
Deferasirox is a relatively new drug and is not yet widely available. It is approved for use in the United States, Europe, and other countries. The drug is generally well tolerated, with the most common side effects being nausea, vomiting, and diarrhea.
Some companies in the Deferasirox market include Novartis, Teva Pharmaceuticals, and Mylan. Show Less Read more